NCT04123418: Phase 1: A Study of WVT078 in Patients With Multiple Myeloma (MM)
Updated: Feb 10
RRMM
NCT04123418: Phase 1: A Study of WVT078 in Patients With Multiple Myeloma (MM)
A Study of WVT078 in Patients With Multiple Myeloma (MM)
The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)
Sponsor
Novartis Pharmaceuticals
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT04123418
Official Title: A Phase I, Open-label, Multicenter, Study of WVT078 in Subjects With Relapsed and/or Refractory Multiple Myeloma
First Posted : October 10, 2019
Click here to see details on ClinicalTrials.gov
Anti-BCMA/Anti-CD3 Bispecific Antibody WVT078
Anti-BCMA/CD3 Bispecific Antibody WVT078
BCMA x CD3 Bispecific Antibody WVT078
WVT 078
WVT-078
WVT078
Drug: WHG626
Locations
United States, Georgia
United States, Minnesota
United States, Wisconsin
Australia, Victoria
Europe
Germany
Italy
Spain
Norway
Asia
Israel
Japan